New findings and key questions in hematopoietic stem cell transplantation

Medical Mycology

Volumn 43, Issue SUPPL.1, 2005, Pages

  Cordonnier, Carl ^a   Botterel, F ^a   Maury, S ^a   Pautas, C ^a   Kuentz, M ^a   Bretagne, S ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

Allogeneic stem cell transplantation; Aspergillosis

Indexed keywords

ANTIFUNGAL AGENT; BIOLOGICAL MARKER; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; FLUCONAZOLE; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; ITRACONAZOLE; VINCA ALKALOID;

ADOPTIVE IMMUNOTHERAPY; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; ASPERGILLOSIS; ASPERGILLUS; CAUSE OF DEATH; CHRONIC MYELOID LEUKEMIA; DRUG POTENTIATION; EARLY DIAGNOSIS; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION RISK; LIVER TOXICITY; NONHUMAN; RISK REDUCTION; TREATMENT PLANNING;

ASPERGILLOSIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INCIDENCE; TRANSPLANTATION, HOMOLOGOUS;

EID: 22844441963     PISSN: 13693786     EISSN: None     Source Type: Journal    
DOI: 10.1080/13693780400020022     Document Type: Article

References (25)

1. Marr KA. Epidemiology and outcome of mold infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34: 909-917.
2. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32: 358-366.
3. Hebart H, Bollinger C, Fisch P, et al. Analysis of T-cell responses to Aspergillus fumigatus antigens in healthy individuals and patients with hematologic malignancies. Blood 2002; 100: 4521-4528.
4. Marty FM, Lee SL, Fahey MM, et al. Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. Blood 2003; 102: 2768-2776.
5. Couriel D, Saliba R, Hicks K, et al. Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood 2004; 104: 649-654.
6. Offner F, Cordonnier C, Ljungman P, et al. Impact of previous aspergillosis on the outcome of bone marrow transplantation. Clin Infect Dis 1998; 26: 1098-1103.
7. Fukuda T, Boeckh M, Guthrie KA, et al. Invasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant center. Biol Blood Marrow Transplant 2004; 10: 494-503.
8. Cordonnier C, Maury S, Pautas C, et al. Secondary prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients. Bone Marrow Transplant 2004; 33: 943-948.
9. Marr KA, Crippa F, Leisenring W, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004; 103: 1527-1533.
10. Winston DJ, Maziarz RT, Chandrasekar PH, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med 2003; 138: 705-713.
11. Winston DJ, Emmanouilides C, Bartoni K, et al. Elimination of Aspergillus infection in allogeneic stem cell transplant recipients with long-term itraconazole prophylaxis: prevention is better than treatment. Blood 2004; 104: 1581-1582.
12. Bretagne S, Marmorat-Khuong A, Kuentz M, et al. Serum Aspergillus galactomannan antigen testing by sandwich ELISA: practical use in neutropenic patients. J Infect 1997; 35: 7-15.
13. Maertens J, Verhaegen J, Lagrou K, et al. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 2001; 97: 1604-1610.
14. Hebart H, Loffler J, Meisner C, et al. Early detection of Aspergillus infection after allogeneic stem cell transplantation by polymerase chain reaction screening. J Infect Dis 2000; 181: 1713-1719.
15. Costa C, Costa JM, Desterke C, et al. Real time PCR coupled with automated DNA extraction and galactomannan antigen ELISA detection for diagnosis of invasive aspergillosis in serum. J Clin Microbiol 2002; 40: 2224-2227.
16. Marr KA, Balajee SA, McLaughlin L, et al. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis 2004; 190: 641-649.
17. Buschheidt D, Hummel M, Schleiemacher D, et al. Prospective clinical evaluation of a LightCycler™-mediated polymerase chain reaction assay, a nested-PCR assay and a galactomannan enzyme-linked immunosorbent assay for detection of invasive aspergillosis in neutropenic cancer patients and haematological stem cell transplant recipients. Br J Haematol 2004; 125: 196.
18. Martino R, Caballero MD, Canals C, et al. Reduced intensity conditioning reduces the risk of severe infecction after allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 2001; 28: 341-347.
19. Junghanss C, Marr KA, Carter RA, et al. Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoeitic stem cell transplantation: a matched control study. Biol Blood Marrow Transplant 2002; 8: 512-520.
20. Fukuda T, Boeckh M, Carter RA, et al. Risk and outcomes of invasive fungal infections in recipients of allogeneic hematopoeitic stem cell transplants after nonmyeloablative conditioning. Blood 2003; 102: 827-833.
21. Kojima R, Kami M, Nannya Y, et al. Incidence of invasive aspergillosis after allogeneic hematopoietic stem cell transplantation with a reduced-intensity regimen compared with transplantation with a conventional regimen. Biol Bone Marrow Transplant 2004; 10: 645-652.
22. Sorror ML, Maris MB, Storer B, et al. Comparing morbidity and mortality of HLA-matched unrelated donor hemaopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplant comorbidities. Blood 2004; 104: 961-967.
23. Bozza S, Gaziano R, Spreca A, et al. Dendritic cells transport conidia and hyphae of Aspergillus fumigatus from the airways to the draining lymph nodes and initiate disparate Th responses to the fungus. J Immunol 2002; 168: 1362-1371.
24. Cenci E, Mencacci A, Bacci A, et al. T cell vaccination in mice with invasive pulmonary aspergillosis. J Immunol 2000; 165: 381-388.
25. Bozza S, Perruccio K, Montagnoli C, et al. A dendritic cell vaccine against invasive aspergillosis in allogeneic hematopoietic transplantation. Blood 2003; 102: 3807-3814.